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introduction
There is an urgent need for biomarkers facilitating diagnosis of 
Alzheimer’s disease (AD) and Parkinson’s disease (PD) at an early 
stage in the disease course before the onset of clinical symptoms 
and to predict disease progression. For AD, the 42 amino acid 
form of β-amyloid (Aβ42) reflecting Aβ deposition in plaques, 
total tau (T-tau) reflecting the intensity of neuroaxonal degen-
eration, and phosphorylated tau (P-tau) reflecting the amount of 
brain tangle pathology are promising cerebrospinal fluid (CSF) 
biomarkers for early detection (1), but they do not cover all the 
neurodegenerative processes involved. For PD and dementia 
with Lewy bodies (DLB), no diagnostic or prognostic CSF or 
blood biomarkers exist, except for α-synuclein in CSF (2). The 
use of Aβ42, tau proteins, and α-synuclein for the diagnosis and 
prognosis of AD and PD is challenged by the high intra- and 
inter-center variability in biomarker concentration measure-
ments (3–5). The variability in measurements is likely caused by 
differences in pre-analytical and analytical protocols for sample 
collection, sample handling, and local assay handling (3, 6–10), 
as well as by inconsistencies in kit production with batch-to-batch 
and even within-plate variation (11, 12).
Biomarkers for Alzheimer’s and Parkinson’s Disease 
(BIOMARKAPD) was a European multicenter study, funded 
by EU Joint Programme-Neurodegenerative Disease Research 
(JPND), designed to standardize the assessment of existing assays 
and to validate novel fluid biomarkers for AD and PD. To sup-
port these objectives, BIOMARKAPD has established a central 
biobank and a virtual biobank for neurodegenerative diseases. 
Samples for the central biobank have been collected and handled 
according to standardized operating procedures (13). The virtual 
biobank provides an overview of the local sample stock at each 
site. In this article, we will give an overview of clinical data, avail-
ability of samples, and the methods for sample collection and 
processing. Finally, we will explain the procedures for requesting 
samples.
Materials and Methods
central Biobank
Study Population
Inclusion criteria for subjects in the central biobank of 
BIOMARKAPD were a diagnosis of normal cognition, mild cog-
nitive impairment (MCI), AD, PD, dementia with Lewy bodies 
(DLB), frontotemporal dementia (FTD), vascular dementia (VaD), 
progressive supranuclear palsy (PSP), multiple system atrophy 
(MSA), or another type of dementia. Subjects were required to 
be at least 55 years old (in the MCI group) or at least 40 years old 
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(in all other diagnostic groups). Subjects with normal cognition 
were clinically evaluated and were required to score above the 
10th percentile on the age and education corrected mini-mental 
state examination (MMSE) (14). MCI was defined as referral to 
a memory clinic because of cognitive complaints in the absence 
of dementia. MCI subtypes could be defined post hoc based on 
neuropsychological test performance or CDR score. Subjects with 
PD were clinically diagnosed according to the UKPDBB criteria 
(15) or Gelb criteria (16). Subjects with dementia had a minimum 
score of 18 on the MMSE and were clinically diagnosed accord-
ing to the NINCDS-ADRDA criteria for probable or possible AD 
(17), Neary criteria for FTD (18), NINDS-AIREN criteria for 
VaD (19), and McKeith criteria for DLB (20). Exclusion criteria 
for all subjects were contra-indications for lumbar puncture and 
other obvious causes of cognitive impairment such as strokes, 
severe depression, or endocrine disorders.
clinical Data
The central biobank collected information on age, gender, edu-
cation, clinical history [e.g., diagnosis, medication use, a selec-
tion of co-morbid disorders (cardiovascular, cerebrovascular, 
neurological, endocrine, somatic, and psychiatric disorders)], 
smoking habits and alcohol intake, physical examination [i.e., 
blood pressure, height, weight, and body mass index (BMI)], 
general cognition (CDR and MMSE), neuropsychological test 
performance for the domains of memory, fluency, visuospatial 
construction, attention, and executive functioning (expressed as 
raw scores and as z-scores according to local norms corrected for 
age, gender, and education), procedures for sample collection and 
processing, and the availability of imaging data (e.g., MRI, PET). 
Clinical data were collected within a timeframe of 6  months 
around blood/CSF collection.
standardized Operating Procedures
Samples for the central biobank were collected according to defined 
biobanking pre-analytical standard operating procedures (SOPs) 
of the BIOMARKAPD project. For CSF collection, processing, 
and storage, we adhered to the BIOMARKAPD SOP published by 
del Campo et al. (13). For plasma and serum samples, we adhered 
to the biobanking guidelines published by Teunissen et al. (21). 
In addition, we recommended a 60 min minimum clotting time 
for blood for serum samples in accordance with the instructions 
of the tube manufacturer. For blood for DNA samples, we recom-
mended storage at maximal −20°C consistent with the guidelines 
by Teunissen et al. (22). Centers were asked to report deviations 
from the SOP.
sample collection, Processing, and storage
Tubes for sample collection and storage were distributed by 
Integrated BioBank of Luxembourg (IBBL). Blood samples were 
collected in the following polypropylene tubes: 10  mL EDTA 
[Becton, Dickinson and Company (BD), ref. 367525] for plasma, 
4 mL EDTA (BD, ref. 368861) for whole blood, and 10 mL clot acti-
vator tubes (CAT) (BD, ref. 367896) for serum. CSF was collected 
in 10 mL polypropylene tubes (Sarstedt, ref. 62.610.018). Blood 
samples for DNA were not centrifuged and stored at maximal 
−20°C. All other samples were centrifuged at room temperature 
at 2,000 × g (min 1,800 × g, max 2,200 × g) and stored at −80°C. 
A maximum of 2 h was allowed between collection and freezing. 
A more detailed description of the SOP used for the collection 
of samples for the central biobank can be found elsewhere (13). 
For every subject 2 mL CSF, 2 mL serum, and 2 mL plasma were 
stored in 0.5 aliquots (in 0.5 mL Matrix 2D Thermo tubes) and 
4  mL blood was stored for DNA isolation. Primary specimens 
and samples derivatives were coded with a three-letter center 
code and a subject number. Samples were at first stored locally, 
and then shipped on dry ice to IBBL for long-term storage. DNA 
extraction was performed at the IBBL. Samples and associated 
data were processed and stored at IBBL in compliance with ISO 
9001:2008, NF S96-900: 2011, and ISO 17025:2005 standards and 
the ISBER Best Practices.
Virtual Biobank
The virtual biobank provides an estimation of the number of 
samples, and clinical (i.e., age, gender, education, CDR scores, 
MMSE scores, Parkinson scales, neuropsychological test results, 
information on medication use, and co-morbid disorders) and 
other biomarker data (i.e., MRI data, amyloid PET, dopamine 
SPECT) available at each center of subjects with normal cognition, 
MCI, AD, PD, PD with dementia, DLB, FTD, VaD, PSP, MSA, 
and other types of dementia. Retrospectively collected samples 
had been collected according to the center’s own SOPs. Centers 
that changed to the standardized BIOMARKAPD SOP during the 
project reported the transition date. All samples remained stored 
on site.
ethics
Centers received approval from their local Ethical Committee and 
all subjects provided informed consent. All human research was 
conducted in accordance with the principles of the Declaration 
of Helsinki.
results
central Biobank
Sample collection for the central biobank was performed in the 
period October 2013–December 2015. A total of 14 European 
centers have contributed samples and data to the central biobank. 
Currently, the central biobank database contains clinical infor-
mation on 419 subjects, of which 49 had normal cognition, 
117 MCI, 164 AD, 24 FTD, 3 VaD, 11 DLB, 25 PD, 5 PD with 
dementia, 3 PSP, 1 MSA, and 18 other types of dementia (i.e., 
either unknown or mixed pathology). From almost all subjects 
CSF samples (n = 410), plasma samples (n = 413 subjects), serum 
samples (n = 414), and DNA samples (n = 414) are available at 
the central biobank. At the local sites, MRI imaging data are 
available from 299 subjects, SPECT from 6 subjects, amyloid PET 
from 14 subjects, and FDG-PET from 28 subjects. Table 1 lists 
demographic information, neuropsychological tests results, and 
available imaging data according to diagnostic group. At least 1 
neuropsychological test result was available from 307 subjects. 
The deviations reported from the SOP are shown in Table 2. The 
most common deviation (82%) was the use of a different needle 
than the 25G atraumatic needle. For most lumbar punctures, 
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TaBle 1 | central biobank subject characteristics, z-scores on neuropsychological tests, and biomarker data available according to diagnostic group.
Total 
(n = 419)
normal cognition 
(n = 49)
Mci 
(n = 117)
aD  
(n = 164)
FTD  
(n = 24)
VaD 
(n = 3)
DlB 
(n = 11)
PD 
(n = 25)
PD with  
dementia (n = 5)
PsP  
(n = 3)
Msa 
(n = 1)
Other dementia 
(n = 18)
Demographics, n 419 49 117 164 24 3 11 25 5 3 1 18
Age, mean (SD) 68.0 (9.3) 62.5 (9.9) 67.1 (9.2) 70.6 (8.5) 63.8 (7.4) 72.3 (5.5) 75.6 (8.9) 68.0 (7.5) 72.2 (5.9) 54.7 (5.9) 80.0 (0) 65.8 (10.1)
Male, % (n) 49 (205) 61 (30) 53 (62) 37 (60) 63 (15) 67 (2) 73 (8) 60 (15) 60 (3) 67 (2) 0 (0) 44 (8)
Education, mean years 
(SD)
9.9 (3.7) 12.2 (2.9) 10.3 (3.4) 9.6 (3.8) 7.9 (3.4) 7.3 (3.1) 8.3 (3.5) 8.9 (3.3) 11.0 (2.8) 14.0 (3.5) 5.0 (0) 8.9 (3.8)
MMse, n 386 49 109 150 23 3 11 17 5 3 1 15
Mean (SD) 23.9 (5.3) 27.6 (2.6) 27.0 (2.2) 21.1 (5.1) 22.9 (5.6) 25.3 (1.5) 21.1 (6.6) 26.3 (5.5) 22.6 (5.9) 22.3 (3.8) 23.0 (0) 19.1 (7.7)
cDr overall, n 283 44 82 113 16 2 4 3 1 3 0 15
Mean (SD) 0.8 (0.5) 0.2 (0.3) 0.5 (0.1) 1.1 (0.4) 1.1 (0.6) 1.0 (0) 0.8 (0.3) 1.7 (1.2) 0.5 (0) 1.0 (0) – 1.2 (0.7)
nPa (at least  
1z-score), n
307 45 100 108 17 3 7 10 3 3 0 11
Word list immediate 
recall
−1.8 (1.5) −0.3 (1.1) −1.5 (1.3) −2.8 (1.2) −2.8 (1.9) −1.8 (0.4) −2.3 (1.2) −0.4 (2.2) − −1.8 (2.0) − −2.2 (0.5)
Word list delayed recall −1.7 (1.4) −0.7 (0.9) −1.5 (1.4) −2.5 (1.1) −1.7 (1.0) −2.2 (0.6) −2.1 (1.7) 0.4 (0.4) − −1.4 (1.6) – −2.4 (0.6)
Story immediate recall −1.2 (1.7) 0 (0.9) −1.3 (2.0) −2.4 (0.8) −2.7 (0) – – −3.9 (0) – – – −2.1 (0.4)
Story delayed recall −0.8 (1.9) −0.1 (0.9) −1.7 (2.0) −0.2 (3.6) – – – −4.8 (0) – – – −2.4 (0)
Fluency −1.0 (1.4) −0.5 (1.1) −0.8 (1.5) −1.5 (1.2) −1.6 (1.2) −1.3 (1.4) 0 (1.4) −0.9 (0.9) – 1.0 (2.8) – −1.1 (1.2)
Copy figures −0.7 (1.4) −1.4 (0.9) −0.4 (1.4) −0.9 (1.4) −1.4 (1.6) 0.8 (0.5) −0.7 (1.5) 0.4 (1.1) – −0.9 (2.2) – −1.2 (1.2)
TMTA −1.2 (1.4) −0.8 (1.4) −0.9 (1.3) −1.6 (1.2) −1.9 (1.6) −1.5 (0.6) −0.2 (1.7) −0.3 (0.8) – 1.6 (3.7) – −2.5 (0.8)
TMTB −1.5 (1.7) −1.0 (1.4) −1.2 (1.7) −2.1 (1.6) −2.4 (1.6) −2.0 (1.6) −2.1 (1.3) 1.3 (0.1) – 1.8 (3.5) – −2.0 (1.3)
Fasted, % (n) 35.0 (140) 4.4. (2) 39.8 (45) 30.7 (47) 54.2 (13) 66.7 (2) 36.4 (4) 72.0 (18) 40.0 (2) 0 100 (1) 35.3 (6)
erythrocyte count 
>500/μl, % (n)
5.0 (20) 8.9 (4) 3.5 (4) 7.0 (11) 0 0 0 0 0 0 0 5.9 (1)
Mri, na 299 45 90 110 21 2 3 5 3 3 1 16
sPecT, na 6 0 0 1 0 0 2 1 2 0 0 0
amyloid PeT, na 14 2 1 8 1 0 0 0 0 1 0 1
FDg-PeT, na 28 1 6 11 4 0 0 0 0 1 0 5
MMSE, mini-mental state examination; CDR, Clinical dementia Rating; NPA, neuropsychological assessment; TMT, Trail Making Test; MCI, mild cognitive impairment; AD, Alzheimer’s disease; FTD, frontotemporal dementia; VaD, 
vascular dementia; DLB, dementia with Lewy bodies; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; MSA, multiple system atrophy.
Data are mean (SD), count or valid percent.
aNot in central biobank, but available at local sites.
TaBle 2 | Deviations from the sOP reported for samples in the central biobank.
sOP recommendation number of deviations reason (number of subjects)
csF collection
Withdrawal of 10 mL CSF (+2 mL for clinical 
purposes)
14 Slow flow/flow stopped (2); unknown (7); difficulty with positioning (1); 
patient did not want to continue (2); impossible, no reason specified (2)
25G atraumatic needle 336 Neurologist preferred traumatic needle (79); atraumatic used, but different 
diameter: 25G not available (238), impossible with 25G (19)
LP location: intervertebral space L3-L5 0 –
Polypropylene tubes 0 –
Erythrocyte count <500/μL 20 Unknown (20)
csF processing
Centrifuge at 2,000 × g (or between 1,800 and 
2,200 × g) for 10 min at RT
5 2,000 × g centrifuge not available (centrifuged at 1,120 × g) (5)
Maximum 2 h between collection and freezing (or 
temporarily store at 4°C)
1 Delay in sample delivery (1)
Freeze at −80°C 0 –
Maximum of 2 freeze and thaw cycles 0a –
Blood for plasma, processing
Centrifuge at 2,000 × g (or between 1,800 and  
2,200 × g) for 10 min at RT
5 2,000 × g centrifuge not available (centrifuged at 1,120 × g) (5)
Maximum 2 h between collection and freezing (or 
temporarily store at 4°C
13 Delay in sample delivery (1); unknown (12)
Freeze at −80°C 0 –
Limit freeze and thaw cycles 0a –
Blood for serum, processing
Centrifuge at 2,000 × g (or between 1,800 and 
2,200 × g) for 10 min at RT
5 2,000 × g centrifuge not available (centrifuged at 1,120 × g) (5)
Maximum 2 h between collection and freezing (or 
temporarily store at 4°C)
13 Delay in sample delivery (1); unknown (12)
At least 30 min (but preferably >60 min) between 
collection and centrifugation
10b Mistake <30 min (10)
Freeze at −80°C 0 –
Limit freeze and thaw cycles 0a –
Whole blood for Dna, processing
Freeze below −20°C 0 –
SOP, standardized operating procedures; LP, lumbar puncture; RT, room temperature. Data are number of subjects in which a deviation of the SOP occurred.aOne cycle: CSF (50), 
plasma (5) and serum (55).
bClotting time: between 30 and 50 min (23) and between 50 and 59 min (35).
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this needle was unavailable (n = 239), it was impossible to col-
lect CSF with this needle (n = 19) or the neurologist preferred a 
traumatic needle (n = 79). None of the samples had more than 
the maximum of two freeze and thaw cycles, while 12% of the CSF 
samples, 1% of the plasma samples, and 13% of the serum samples 
underwent one freeze and thaw cycle. If the deviation related to 
needle use and number of freeze and thaw cycles was not taken 
into account, adherence to the BIOMARKAPD SOP was 91% for 
CSF collection and centrifugation, 96% for plasma collection and 
centrifugation, 93% for serum collection and centrifugation, and 
100% for DNA collection and processing.
Virtual Biobank
Currently, 21 centers have contributed data to the virtual biobank 
of BIOMARKAPD. The virtual biobank contains information on 
CSF samples from 7,550 subjects, EDTA plasma samples from 
8,676 subjects, and serum samples from 8,141 subjects. So far, 
11 centers have reported that they followed, or changed to, 
the BIOMARKAPD SOP for sample collection and processing. 
Table 3 lists the number of subjects per diagnostic group with 
CSF, EDTA plasma, and serum samples available.
Discussion
As part of BIOMARKAPD, a large central and virtual biobank 
with body fluids were established from over 9,000 subjects with 
neurodegenerative disorders. The central biobank contains sam-
ples from more than 400 subjects of which nearly 40% have AD. 
Adherence to the BIOMARKAPD SOP was high (>91%) for the 
collection and processing of CSF, plasma, and serum and blood 
samples. The virtual biobank contains CSF samples from over 
7,500 subjects, plasma samples from over 8,600 subjects, and 
serum samples from over 8,100 subjects. Samples for the virtual 
biobank have been collected according to varying local SOPs. 
TaBle 3 | number of subjects in virtual biobank with csF, eDTa plasma, 
and serum samples available according to diagnostic group.
csF eDTa plasma serum
Normal cognition, n 890 1,831 1,316
MCI, n 1,969 1,894 2,066
AD, n 2,420 2,440 2,349
FTD, n 612 621 647
VaD, n 156 187 151
DLB, n 277 282 279
PD 439 720 748
PD with dementia, n 157 243 219
PSP, n 148 146 115
MSA, n 68 57 38
Other dementia, n 414 255 213
Total 7,550 8,676 8,141
CSF, cerebrospinal fluid; MCI, mild cognitive impairment; AD, Alzheimer’s disease; 
FTD, frontotemporal dementia; VaD, vascular dementia; DLB, dementia with 
Lewy bodies; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; 
MSA, multiple system atrophy.
Data are number of subjects with CSF, EDTA plasma, or serum samples available.
October 2015 | Volume 6 | Article 2166
Reijs et al. The central biobank and virtual biobank of BIOMARKAPD
Frontiers in Neurology | www.frontiersin.org
However, so far more than half of the centers have reported 
adopting the BIOMARKAPD SOP in the course of the project.
requesting samples from the central or  
Virtual Biobank
Researchers in the field of neurodegenerative disorders interested 
in requesting samples from the central biobank or from the virtual 
biobank of BIOMARKAPD are invited to consult the following 
website: http://jpnd.arone.com/. Requests should meet the objec-
tives of BIOMARKAPD project, i.e., to standardize the assess-
ment of existing assays and to validate novel fluid biomarkers for 
AD and PD. Sample requests will be evaluated by the Analysis 
Advisory Board (AAB). Approval from the AAB will depend on 
scientific quality, whether the sample request meets the objectives 
of BIOMARKAPD, and sample availability. Furthermore, the 
sample request must meet the following three criteria. First, the 
researcher must demonstrate that the analysis complies with local 
medical ethical standards, for example, by showing regulatory 
approval of a medical ethical committee (MEC), institutional 
review board (IRB), or equivalent. Second, technical character-
istics of assays such as linearity, recovery, specificity, imprecision, 
sensitivity, and lot-to-lot variability have already been established 
and of sufficient performance. Third, prior to the request, the diag-
nostic or prognostic value of the assay should have been already 
demonstrated in at least 20 controls and 20 diseased subjects. For 
the central biobank, fees will apply to cover the costs for sample 
and data collection, processing, and sample storage. Before ship-
ment a material transfer agreement (MTA) needs to be signed.
For the virtual biobank, individual centers can decide on 
a case-to-case basis whether or not they would like to provide 
samples and which conditions will apply. When requesting sam-
ples from the virtual biobank, contact details will be provided of 
centers that are interested in meeting the sample request. Centers 
may use the MTA from the central biobank for the shipment of 
samples. Detailed information on the methodology of sample 
preparation and handling, and available clinical information 
should be requested directly from the center.
conclusion
The central and virtual biobanks of BIOMARKAPD provide 
access to a large repository of CSF and blood samples for research-
ers in the field of neurodegenerative disorders, enabling progress 
in the clinical use of biomarkers for the diagnosis and prognosis 
of neurodegenerative disorders.
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